Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety study of MP03-33 nasal spray in chronic allergic or nonallergic rhinitis
ACTRN12606000348550Phase 3Recruiting
- Sponsor
- MedPointe Healthcare
- Start
- Jul 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of azelastine in allergic rhinitis (AR), Perennial Nonallergic Rhinitis (NAR) and non-allergic rhinitis (NAR) (2 arms), sponsored by MedPointe Healthcare. Primary endpoints: Safety and tolerability measured by frequency of patient-reported adverse events and Direct visual examination of the nasal mucosa. Started Jul 2006; status: recruiting.
02
Drugs
azelastine
03
Conditions
allergic rhinitis (AR)Perennial Nonallergic Rhinitis (NAR)non-allergic rhinitis (NAR)
Beyond the preview
Go deeper on ACTRN12606000348550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000348550.